Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 5NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 5Ovarian Neoplasms 4Central Nervous System Neoplasms 4Carcinoma, Ovarian Epithelial 4Neoplasms, Plasma Cell 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Myeloid, Acute 3Leukemia 3Gliosarcoma 3Glioblastoma 3Unspecified Adult Solid Tumor, Protocol Specific 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Fallopian Tube Neoplasms 2Congenital Abnormalities 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Brain Neoplasms 2Astrocytoma 2Urinary Bladder Neoplasms 1

Interventions

Cyclophosphamide 24Vincristine 20Carboplatin 18Doxorubicin 15Etoposide 14Melphalan 12Radiotherapy 11Filgrastim 11Cisplatin 11Magnetic Resonance Spectroscopy 10Isotretinoin 10Specimen Handling 9Peripheral Blood Stem Cell Transplantation 9dinutuximab 8Biopsy 8X-Rays 7Topotecan 7Temozolomide 7aldesleukin 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Busulfan 6sargramostim 5Irinotecan 5Vindesine 4Neoadjuvant Therapy 4Ipilimumab 4Ifosfamide 4Dacarbazine 43-Iodobenzylguanidine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neuroblastoma × Drug Therapy × Clear all
NCT00389766 2013-07-10

High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Withdrawn
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡